fbpx Why is migraine the second most disabling disease worldwide? | Progress In Mind

Why is migraine the second most disabling disease worldwide?

Migraine affects all areas of life. Its sudden unpredictable onset with severe incapacitating headache and disabling neurological symptoms can make it impossible to carry out normal everyday activities within the family, at work, school, and socially — causing suffering for people with migraine and their families, friends, and work colleagues.

Migraine is common and is experienced by 1 in 10 people worldwide, particularly women — in the US, it affects 1 in 5 women and 1 in 16 men.2 It is the second most disabling disease globally.3

The disability increases with the number of monthly migraine days (MMDs) — 70% of patients with episodic migraine (4–6 MMDs) and 90% of those with chronic migraine (at least 15 MMDs) experience moderate to very severe disability.4

Migraine is a women’s health issue

The burden experienced by people who have migraine is substantial

Around one in four people with migraine report missing work or school, one in two report being unable to do housework, and one in three report missing family or social activities.5

80% of 255 people with chronic migraine report reduced participation in family activities6

Professor Dodick’s patients described the toll of their severe migraine attacks on their lives, and the guilt they felt at letting down their family, friends and work colleagues and being unable to plan and provide commitment for events. They highlighted how their migraines had adversely impacted their behavior in terms of having children, the number of hours they worked, and taking early retirement.

Their work experiences have been demonstrated in studies of other people with migraine with:

  • 13% reporting a reduction in work productivity (absenteeism)
  • 48% reporting a reduction in work productivity while working (presenteeism)
  • 52% reporting impaired overall work productivity (absenteeism and presenteeism combined) and daily activities7

The Chronic Migraine Epidemiology and Outcomes (CaMEO) study confirms the adverse impact of migraine on career development including missed promotion, reduced number of working hours, and early retirement,8 said Professor Dawn Buse, Albert Einstein College of Medicine, Yeshiva University, NY.

Overall, migraine imposes financial and personal burdens on migraineurs and their families6 and can lead to social isolation, disrupted personal relationships, and fewer if any children.9

Migraine is accompanied by a high prevalence of comorbid psychiatric disorders

Anxiety and depression are 2–5 times more common among people with migraine than in the general population

Professor Dodick’s patients reported that their migraines had led them to experience severe depression and anxiety, and one described occasional suicidal thoughts. These comorbid psychiatric disorders are common among people with migraine, commented Professor Buse. Over 50% of people with migraine report anxiety and sleep disorders, nearly 50% report depression, and up to 43% report post-traumatic stress disorder,10 with depression and anxiety comorbidity rates increasing with MMD frequency.11

People with migraine are also three times more likely to have bipolar disorder and twice as likely to manifest suicidal behaviors,12 added Professor Buse.

Most people living with migraine are not receiving appropriate treatment

People with migraine often experience migraine for decades — in pain, frustrated, distraught, and looking for answers

Only 26% of those with episodic migraine13 and less than 5% of those with chronic migraine14 have consulted a healthcare professional and received an accurate diagnosis, said Professor Dodick. Yet preventive therapy leads to a reduction in MMDs at least 50% compared to baseline and clinically meaningful improvement in patient-reported outcome measurements.15

The American Headache Society therefore recommends that preventive therapy should be offered when a patient has:

  • at least 3 MMDs associated with severe disability
  • at least 4 MMDs associated with moderate disability
  • at least 6 MMDs associated with no disability

Professor Dodick concluded that it is critical for healthcare providers and patients to develop a close connection to determine the best treatment strategy to mitigate the decreased productivity at work and school, depression and anxiety, and social, financial, and societal burden of migraine and improve outcomes for patients.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References
  1. migraineresearchfoundation.org/
  2. migraineresearchfoundation.org/about-migraine/migraine-in-women/
  3. Vos T, et al. Lancet 2017;390:1211–59.
  4. Blumenfeld A, et al. Cephalalgia 2011;31:301–15.
  5. Lipton R, et al. Neurology 2007;68:343–9.
  6. Buse D, Mayo Clin Proc 2016;91:596–611.
  7. Martelletti P, et al. J Headache Pain 2018;19:115–25.
  8. Buse D, et al Headache 2019;59:1286–99.
  9. Lampl C, et al. J Headache Pain;2016;17:9.
  10. Minen M, et al. J Neurol Neurosurg Psychiatry 2016;87:741–9.
  11. Chu H, et al. Headache 2018;58:407–15.
  12. Friedman L, et al. Headache. 2018;58:371–80.
  13. Lipton R, et al. Headache 2013;53:81–92.
  14. Dodick D, et al. Headache 2016;56:821–34.
  15. American Headache Society. Headache 2019;59:1–18.
You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country